Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 2 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus ORGARAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 2 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus ORGARAN.
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER vs ORGARAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, accelerating its inhibition of coagulation factors IIa (thrombin), Xa, and others, thereby preventing thrombus formation and extension.
Danaparoid is a low molecular weight heparinoid that exerts its anticoagulant effect by inhibiting factor Xa and, to a lesser extent, factor IIa (thrombin) through binding to antithrombin III and heparin cofactor II.
25,000 units in 250 mL D5W (100 units/mL) continuous IV infusion at 20,000-40,000 units/24 hours; adjust based on aPTT.
Adults: Initial intravenous bolus of 2500 IU (anti-Xa), followed by continuous intravenous infusion of 400 IU/h for 2 hours, then 300 IU/h for 2 hours, then 200 IU/h for 5 days; or subcutaneous injection of 750 IU twice daily. Dose adjusted to maintain anti-Xa levels of 0.5-1.0 IU/mL.
None Documented
None Documented
30-150 minutes (dose-dependent, saturable); mean 60-90 min. Prolonged in hepatic/renal impairment and pulmonary embolism.
Terminal elimination half-life: 18-25 hours (mean ~19 hours) in patients with normal renal function; prolonged in renal impairment (up to 30-40 hours in severe renal failure, CrCl <30 mL/min).
Primarily renal (40-60% as unchanged drug) and reticuloendothelial system; small amount biliary/fecal. Clearance is saturable.
Renal: 40-50% as unchanged drug; biliary/fecal: minimal; small amount metabolized via desulfation and N-acetylation.
Category A/B
Category C
Anticoagulant
Anticoagulant